Margaret A. Horn Sells 2,514 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret A. Horn sold 2,514 shares of Revolution Medicines stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $31.31, for a total value of $78,713.34. Following the completion of the sale, the chief operating officer now directly owns 96,960 shares in the company, valued at approximately $3,035,817.60. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Revolution Medicines Stock Up 0.2 %

Shares of NASDAQ:RVMD traded up $0.07 during trading on Tuesday, reaching $31.00. The stock had a trading volume of 1,343,380 shares, compared to its average volume of 1,105,024. Revolution Medicines, Inc. has a fifty-two week low of $17.03 and a fifty-two week high of $35.50. The stock has a market cap of $3.38 billion, a P/E ratio of -9.87 and a beta of 1.36. The business has a fifty day moving average price of $30.04 and a 200-day moving average price of $26.17.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.10). The business had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative return on equity of 36.46%. Revolution Medicines’s revenue for the quarter was down 58.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.82) EPS. As a group, equities analysts forecast that Revolution Medicines, Inc. will post -3.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on RVMD shares. Needham & Company LLC cut their target price on shares of Revolution Medicines from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Wednesday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Revolution Medicines in a research note on Wednesday, August 2nd. Finally, Oppenheimer increased their target price on Revolution Medicines from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $33.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Belpointe Asset Management LLC purchased a new stake in shares of Revolution Medicines during the 4th quarter valued at $26,000. US Bancorp DE raised its position in shares of Revolution Medicines by 68.1% in the 2nd quarter. US Bancorp DE now owns 1,575 shares of the company’s stock worth $42,000 after buying an additional 638 shares during the period. Strs Ohio acquired a new position in Revolution Medicines in the second quarter valued at $45,000. Point72 Hong Kong Ltd purchased a new stake in Revolution Medicines during the second quarter valued at about $39,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Revolution Medicines by 77.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,132 shares of the company’s stock worth $68,000 after acquiring an additional 1,366 shares during the last quarter.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors.